ライフサイエンスコーパス: oncological

1 This indicates that oncological activity may be based on several mechanisms.

2 systems and, in doing so, contribute to both oncological and clinical NLP research.

3 c breast surgery (OPBS) were to evaluate the oncological and cosmetic outcomes of OPBS.

4 Long-term oncological and functional outcome data are necessary to

5 Lack of uniform PLND, devoid of long-term oncological and functional outcome data are still issues

6 We investigated the oncological and functional outcomes of neoadjuvant chemo

7 mors or tumors in solitary kidneys with good oncological and functional outcomes.

8 th 10,071 individuals across 14 countries in oncological and haematological settings.

9 and feasible surgical option with comparable oncological and improved renal function outcomes compare

10 duced RF irradiations will be beneficial for oncological and nephrological applications, in which the

11 neurologist because of their prominent neuro-oncological and neuro-developmental consequences.

12 treatment of T1b and T2 renal mass, focusing oncological and renal functional outcomes reported in th

13 improves the clinical predictability of the oncological and toxicological results.

14 unicable diseases, including cardiovascular, oncological, and respiratory illnesses.

15 CA-2) antibody, its frequency, and clinical, oncological, and serological associations.

16 eon's perspective on sentinel node and other oncological applications and on the surgical value of nu

17 he surgical, pathological, radiological, and oncological approaches used to treat this disease, but t

18 tinct cytotoxic agents currently used in the oncological armamentarium mediate their clinical benefit

19 58 (59%) of 98 patients for whom results of oncological assessments were available had tumours, most

20 (18)fluorodeoxyglucose uptake and aggressive oncological behavior.

21 s of LKB1 (KL) in cells specifies aggressive oncological behaviour.

22 the importance of striking a balance between oncological benefit and surgical risk.

23 -art glioma treatment aims to maximise neuro-oncological benefit while minimising losses in quality o

24 operative technique that is associated with oncological benefits.

25 c radical cystectomy to identify its role in oncological bladder surgery.

26 Additional obstacles include the cost of oncological care, poor infrastructure, and the scarcity

27 ere prospectively registered at the regional oncological center.

28 Pancreatic cancer is a major oncological challenge due to its aggressive growth and m

29 illustrate the surgical, nephrological, and oncological challenges of this uncommon but important co

30 ces among all 3 groups regarding general and oncological characteristics and functional parameters on

31 silica scaffold retained significantly more oncological characters than those cultured on the conven

32 Consequently, PRP could have relevant oncological clinical applications for the treatment of a

33 ur diagnosis; (iii) exclusion of other neuro-oncological complications; and (iv) at least one of the

34 Thus, the oncological concept of somatic loss of heterozygosity le

35 of fluid within the Douglas pouch raised the oncological concern.

36 otein, a biomarker for the onset of multiple oncological conditions, especially bladder cancer.

37 patients with a solitary kidney can achieve oncological control as well as renal function preservati

38 surgery in penile cancer has shown that good oncological control can be gained by 2 mm margins that a

39 mpectomy for breast cancer aims at achieving oncological control with maximal tissue preservation, th

40 s, including safety, functional results, and oncological control, continue to be reported as the tech

41 rectum, and although this provides excellent oncological control, it is associated with morbidity and

42 assessed the main demographic, clinical, and oncological determinants of survival in the subgroup of

43 ntion to clinical features and demographics, oncological diagnosis, conditioning regimens, neurologic

44 raphic (e.g. age, gender) nor clinical (e.g. oncological diagnosis, type of BMT, time of stroke after

45 ic targets for autoimmune, inflammatory, and oncological diseases.

46 in particular, for systemic applications in oncological disorders.

47 E is a valuable alternative to TTE regarding oncological doctrine and overall survival.

48 wledge into an improved, metastasis-oriented oncological drug development strategy is needed to thwar

49 is one of the common targets considered for oncological drug development.

50 ach are still to be refined for clinical and oncological effectiveness and safety.

51 Oncological effectiveness of ablative techniques is enco

52 g-term cardioprotection without compromising oncological efficacy in doxorubicin-treated children wit

53 resent state of the literature regarding the oncological efficacy of minimally invasive radical cyste

54 eoadjuvant therapy and local excision showed oncological equivalence to major resection (HR = 1.12, P

55 With recent long-term oncological equivalence to radical nephrectomy and renal

56 n tomography/computed tomography imaging for oncological evaluation.

57 ts with bladder cancer and to understand key oncological events in the evolution of this disease.

58 anguage processing can be used as a tool for oncological evidence-based research and quality improvem

59 The primary end point was a composite of oncological factors indicating an adequate surgical rese

60 uld be restricted to patients with favorable oncological factors.

61 orbidity and mortality, together with a high oncological feasibility and hypertrophic efficacy.

62 x proteins (NMPs) have been identified as an oncological "fingerprint" for bladder, renal, and prosta

63 l design, which will lead to more comparable oncological, functional and quality of life outcomes.

64 periment, which is part of the Collaborative Oncological Gene-environment Study (COGS) initiative.

65 The large-scale Collaborative Oncological Gene-environment Study (COGS) presents new f

66 array, iCOGS, developed by the Collaborative Oncological Gene-environment Study (COGS).

67 ment involving four consortia (Collaborative Oncological Gene-environment Study, COGS) and used a cus

68 studies genotyped through the Collaborative Oncological Gene-environment Study.

69 The data indicate that the KL oncological genotype imposes a metabolic vulnerability r

70 t in the Web-based ROGY (Registration System Oncological Gynecology).

71 adjustment disorder in adults with cancer in oncological, haematological, and palliative-care setting

72 in patients with cancer, including those in oncological, haematological, and palliative-care setting

73 tween 1965 and 2009 evaluating the long-term oncological impact of AL were identified by an electroni

74 However, the oncological impacts of a minimally invasive approach to

75 , which, with few exceptions, are mainly for oncological indications and directed against only a hand

76 are mainly being developed and marketed for oncological indications and diseases, such as idiopathic

77 ibitors are currently in clinical trials for oncological indications, and the current results indicat

78 nd discusses the utility of aFP for treating oncological indications.

79 that this poor outcome is due to an inherent oncological inferiority of the traditional abdominoperin

80 , changes in network topology in response to oncological interventions, particularly tumor resection,

81 Excluded were nonsurgical oncological interventions.

82 vide evidence for the strong need for psycho-oncological interventions.

83 assessment criteria for patients with neuro-oncological malignancies undergoing immunotherapy is the

84 tening complications in patients with hemato-oncological malignancies, and early diagnosis is crucial

85 ising area of therapy in patients with neuro-oncological malignancies.

86 of some differences in short-term surrogate oncological markers, LCR was not inferior to OCR in dire

87 Our results suggest that a close oncological monitoring of patients with BRCA2 mutations

88 cies in proteostasis lead to many metabolic, oncological, neurodegenerative, and cardiovascular disor

89 inically important disease models, including oncological, neurological, and cardiovascular diseases.

90 quency of complications without compromising oncological or cosmetic outcomes of the reconstructed br

91 Oncological outcome data is presently lacking.

92 g fecal urgency and incontinence), and three oncological outcome domains (including long-term surviva

93 bidity is common and its impact on long-term oncological outcome is unclear.

94 e therapy translates into improved long-term oncological outcome, is appropriate.

95 Oncological Outcomes after Clinical Complete Response in

96 sis providing compelling evidence that worse oncological outcomes after curative rectal cancer resect

97 is as effective as open surgery in terms of oncological outcomes and preservation of QoL.

98 s have also declined such that morbidity and oncological outcomes are comparable to open partial neph

99 New data on intermediate and long-term oncological outcomes are now available.

100 ts in I/R injury, regenerative capacity, and oncological outcomes await confirmatory studies in human

101 The purpose of this study was to compare oncological outcomes between laparoscopic nephroureterec

102 of the watch-and-wait approach by comparing oncological outcomes between patients managed by watch a

103 ce data regarding intermediate and long term oncological outcomes following MIRC, and most reported s

104 tion (LLR) and open liver resection (OLR) on oncological outcomes for colorectal cancer liver metasta

105 study aims to report short-term clinical and oncological outcomes from the international transanal To

106 No large-scale studies with long-term oncological outcomes have been published.

107 be performed with good short and medium term oncological outcomes in selected patients.

108 verse effect of the laparoscopic approach on oncological outcomes in terms of margins or survival, ad

109 Oncological outcomes in these cases were superior for th

110 onse following surgery and how it relates to oncological outcomes is one potential area, and is revie

111 study aims to compare the perioperative and oncological outcomes of laparoscopic and open liver rese

112 nsufficient evidence regarding the long-term oncological outcomes of MIRC.

113 , P53, and survivin and the association with oncological outcomes of patients treated by radical cyst

114 The aim of this study is to evaluate the oncological outcomes of robotic total mesorectal excisio

115 Low rectal cancer oncological outcomes remain a global challenge, evidence

116 al therapy trials are encouraging, long-term oncological outcomes remain to be elucidated.

117 n associated with less morbidity and similar oncological outcomes to open liver resection for colorec

118 Although a thorough evaluation of oncological outcomes was not possible, the rate of margi

119 and a shorter hospital stay with comparable oncological outcomes when compared with open liver resec

120 copically or percutaneously offers excellent oncological outcomes with single-session therapy.

121 uated (i) the impact of tumor enucleation on oncological outcomes, (ii) the effect of pretherapeutic

122 tion, and Female Sexual Function Index), and oncological outcomes.

123 he potential to improve overall surgical and oncological outcomes.

124 ence of compromise to early and intermediate oncological outcomes.

125 ort perioperative, functional and short-term oncological outcomes.

126 g such surgeries had equivalence in terms of oncological outcomes.

127 tive window and ultimately improve long-term oncological outcomes.

128 The primary endpoints were oncological outcomes.

129 and Mycoses Study Group criteria) in hemato-oncological patients were identified.

130 accuracy for the diagnosis of IFI in hemato-oncological patients.

131 BG assays for the diagnosis of IFI in hemato-oncological patients.

132 he course of progression, leading to several oncological phenomena that are hard to explain with a tr

133 se inhibitors and monoclonal antibodies into oncological practice has opened a new paradigm for treat

134 ded lymph node dissection based on tenets of oncological principles and acceptable short-term oncolog

135 iffering not only in technical approach, but oncological principles as well.

136 to 2-[18F]fluoro-2-deoxyglucose (FDG) as an oncological probe in cultured PC-3 human prostate cancer

137 e risk of port site metastases following uro-oncological procedures.

138 at certain such fusions could be involved in oncological process in AML, and provide a new source to

139 amers as a new drug class to block important oncological processes.

140 resection guidance with the aim of enabling oncological radical surgery and improvement of patient o

141 penia (patients treated for hematological or oncological reasons who are at risk of bleeding), and ch

142 the use of this technology in head and neck oncological reconstruction will be the effect of radioth

143 ed progress is made with applying NLP toward oncological research, incremental gains will lead to lar

144 mproved diagnosis and therapy, especially in oncological research.

145 ndpoints were the safety and adequacy of the oncological resection criteria.

146 mapping were performed during open standard oncological resection.

147 n system exists for mandibular defects after oncological resection.

148 s, by improving the accuracy and outcomes of oncological resections.

149 with a particular focus on postoperative and oncological results and on functional outcomes.

150 ospective or retrospective studies reporting oncological results for intervals longer or shorter than

151 partial nephrectomy also provides equivalent oncological results for larger renal tumors including th

152 cancers by ELAPE did not improve short-term oncological results, when compared with conventional APE

153 es in demography, tumor characteristics, and oncological results.

154 rioperative morbidity and mortality and good oncological results.

155 s clear, but there is some concern about the oncological risk.

156 ic flexure resection were analyzed to assess oncological safety as well as early and medium-term outc

157 averted permanent colostomy without loss of oncological safety at 3 years.

158 ow include nipple-sparing mastectomy but its oncological safety is still controversial.

159 ely limit the utility of nanomedicine in the oncological setting.

160 issue that has never been discussed from the oncological standpoint.

161 an serve as a point of comparison for future oncological studies at similar institutions.

162 Specialized approaches combining oncological surgery and plastic surgery techniques are c

163 imally invasive techniques into the realm of oncological surgery are hindered by lack of accurate vis

164 geons rigorously adhere to the principles of oncological surgery.

165 A careful oncological surveillance pretransplant as well as posttr

166 urthermore, SMC2 represents a new target for oncological therapeutic intervention.

167 h surgical and non-surgical first-line neuro-oncological therapies.

168 ompounds in food should not adversely affect oncological therapy but rather could successfully aid on

169 Nine patients responded to immunotherapy or oncological therapy, but neurological relapses, without

170 rome development, 17 of 33 patients received oncological treatment (nine also immunotherapy), 10 immu

171 al therapy but rather could successfully aid oncological treatment by regulating the quantities of th

172 Radiotherapy is a primary oncological treatment modality that also damages normal

173 ences in functional outcomes following neuro-oncological treatment, we review mounting evidence demon

174 of solid tumors in the development of modern oncological treatments.

175 vivo, in the selection and planning of neuro-oncological treatments.

176 r tumors of 7 cm or less provides equivalent oncological tumor control to radical nephrectomy with ma

177 ically mutated genes associated with diverse oncological types to colorectal and breast cancers throu

178 latively high ratio of exon 4-excluded neuro-oncological ventral antigen 1 (Nova1(-4)) and intron 2-r

179 adenylation element binding factor and neuro-oncological ventral antigen to specific aspects of synap